Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders
Ardelyx presented real-world data at ASN Kidney Week 2026 showing serum phosphate reductions following XPHOZAH initiation in more than 1,400 adults on dialysis, both with and without phosphate binders. Adjusted mean phosphate reductions at six months ranged from 0.80 to 1.55 mg/dL, with 60-70% of patients remaining on tenapanor at 180 days.
Key figures
- Drug Name
- XPHOZAH (tenapanor)
- Phase Of Trial
- real-world analysis (>1,400 dialysis patients, 6-month follow-up)
- Patients analyzed
- 1400
- Persistence at 180 days
- 60% to 70%
- Probability below 5.5 mg d L
- 16% to 41%
- Adjusted mean phosphate reduction month6
- 0.80 to 1.55 mg/dL
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.